查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1518888

神經退化性疾病的分子診斷：技術成長機會，2024-2028

Molecular Diagnostics for Neurodegenerative Diseases: Technology Growth Opportunities, 2024-2028
出版日期: | 出版商: Frost & Sullivan | 英文 106 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

多組體學整合診斷和照護現場診斷的使用是推進神經退化性疾病分子診斷最有前景的成長機會。

神經退化性疾病(NDD) 為醫療保健系統帶來了重大挑戰，影響著全世界數百萬人，因此早期發現至關重要。目前的診斷策略主要是腦部成像技術，但這要等到症狀變得更加明顯時才會進行。神經元在早期進展過程中發生的微妙變化在與 NDD 相關的結構和功能變化中是無法檢測到的。

這項研究是一項綜合分析，探討了 NDD 分子診斷的技術進步、產業動態、策略見解和成長機會。它捕捉了行業內具有創新產品系列的領先企業、成長中的新興企業和中小企業的作用、關鍵促進因素和阻礙因素以及戰略合作夥伴關係。我們也深入資金籌措、津貼、併購(M&A) 和商業化工作。

總體而言，本研究的目的是深入了解 NDD 分子診斷的演變及其對醫療保健創新和患者照護的影響。

本次調查回答的關鍵問題

1.NDD有哪些分子診斷藥物可供選擇？

2. 與診斷影像相比，廣泛採用分子診斷的主要挑戰和複雜性是什麼？

3.NDD中使用的生物標記的主要訊息是什麼？誰是該領域創新和技術的關鍵和新興參與者？

4.體學技術、智慧 PoC 設備和胞外體介導的診斷如何成為 NDD 的新分子診斷？他們如何提高準確性？

5.學術界和工業界的聯合研究和併購有何戰略意義？

6. 專利如何促進 NDD 診斷和治療方法的進步？

7. NDD 分子診斷存在哪些成長機會？

目錄

戰略問題

  • 為什麼成長如此困難？
  • The Strategic Imperative 8（TM）
  • 神經退化性疾病分子診斷產業三大策略問題的影響
  • 成長機會推動Growth Pipeline Engine（TM）
  • 調查方法

成長機會分析

  • 2050 年失智症疾病負擔預測
  • NDD 研究洞察：2019-2024 年出版品和臨床試驗趨勢
  • NDD：概述和早期診斷的重要性
  • 分割
  • NDD 早期診斷的挑戰
  • 目前 NDD 的診斷方式
  • NDD分子生物標記的來源
  • 分析範圍
  • NDD 診斷：生物標記來源、樣本萃取和分析物
  • 生物標記來源：比較分析
  • NDD生物標記的綜合視角

成長要素

  • 生長促進因子
  • 成長抑制因素

技術分析：腦脊髓液生物標記

  • 基於腦脊髓液的 NDD 分子診斷劑
  • 開發基於 CSF 的 NDD 分子診斷的主要公司
  • 神經診斷的關鍵生物標記：基於腦脊髓液的生物標記物，全球，2024 年

技術分析：血液生物標記

  • NDD 診斷中的血液生物標記
  • 開發 NDD 血液分子診斷的主要公司
  • 新興企業開發基於血液的分子診斷以治療頑固性神經系統疾病
  • 神經診斷的關鍵生物標記：基於血液的生物標記，全球，2024 年

技術分析：唾液生物標記

  • 唾液生物標記：一種方便且痛苦較小的 NDD 診斷方法
  • 新興企業開發基於唾液的 NDD 分子診斷

技術分析：尿液生物標記

  • 用於早期診斷 NDD 的尿液生物標記物
  • 開發基於尿液的 NDD 分子診斷的新興企業

技術分析：眼部生物標記

  • 眼部生物標記：NDD 診斷的新領域
  • 神經生物標記眼部區域的分子變化
  • 開發基於眼科的 NDD 分子診斷的新興企業

技術分析：基於皮膚的生物標記

  • NDD 皮膚生物標記物

NDD分子診斷關鍵生物標記概述

  • NDD 診斷領域產業參與者對生物標記物利用的重要見解
  • 從分子生物標記實驗室到臨床的影響分析

臨床試驗分析

  • NDD 分子診斷的著名臨床試驗
  • 歐洲神經退化性疾病平台 (EPND)：資料和樣本共用的協作方法

NDD分子診斷新趨勢

  • 用於 NDD 診斷中生物標記發現的資料庫和生物庫催化劑
  • 表觀遺傳變化作為 NDD 生物標記
  • 利用巨量資料進行 NDD 診斷的多組體學
  • 胞外體：早期 NDD 診斷的潛在候選者
  • 攜帶式分子診斷設備，實現NDD智慧診斷

主要參與者的策略建議

  • Synaps Dx，美國
  • 法國AgenT生技公司
  • 烏爾沃格爾比歐, 印度
  • 美國共振
  • 紐德克斯，美國

相關人員計劃

  • 著名的 NDD Diagnostics 研究合作和臨床聯盟
  • NDD 診斷公司最近的併購
  • 全球公司和地區對 NDD 診斷的採用情況

資金籌措分析

  • 2019-2024 年美國NDD 分子診斷公共資金概況
  • NIH 對 AD 分子診斷的資助，2019-2024
  • 歐盟研發計劃，2019-2023
  • 2021-2024 年 NDD 分子診斷私人資金籌措概況
  • 2020-2023 年 NDD 分子診斷私人資金籌措概況

專利分析

  • 2019-2024年分子神經生物標記產業智慧財產權趨勢
  • 2019-2024 年 NDD 診斷領域主要參與企業的專利
  • 2019-2024年分子神經生物標記產業智慧財產權趨勢分析

分析師的觀點

  • NDD 中的分子診斷：技術、創新和應用的影響分析
  • NDD 背景下各種分子診斷技術的商業性可用性
  • NDD的分子診斷：技術藍圖

成長機會

  • 成長機會 1：NDD 偵測與管理照護端智慧診斷
  • 成長機會2：NDD綜合評估的綜合診斷方法
  • 成長機會3：NDD領域的外泌體組學和代謝體學

附錄

  • 技術成熟度等級 (TRL)：解釋

下一步

  • 成長機會的好處和影響
  • 下一步
  • 下一步
  • 免責聲明
簡介目錄
Product Code: DAED

Leveraging integrated and point-of-care diagnostics with multiomics represents the most promising growth opportunity to advance molecular diagnostics for neurodegenerative diseases

Neurodegenerative diseases (NDD) pose significant challenges to healthcare systems and affect millions of people worldwide, making early detection crucial. While the current diagnostic strategy is predominantly brain imaging techniques, it is not performed until symptoms are more pronounced. Subtle changes occurring in neural cells during early progression cannot be detected by the structural or functional changes associated with NDDs.

This study is a comprehensive analysis that explores technological advancements, industry dynamics, strategic insights, and growth opportunities in molecular diagnostics for NDDs. It captures the role of leading companies, growing start-ups, and smaller companies with innovative product portfolios and an industry presence, key drivers and restraints, and strategic partnerships. The study also delves into funding, grants, mergers and acquisitions (M&As), and commercialization efforts.

Overall, this study aims to provide insights into the evolving landscape of molecular diagnostics for NDDs and implications for healthcare innovation and patient care.

Key Questions the Study Answers:

1. What are the different molecular diagnostics for NDDs?

2. What are the main challenges and complexities in the widespread adoption of molecular diagnostics compared to imaging diagnostics?

3. What are the primary sources of biomarkers used in NDDs? Who are the key and emerging participants in terms of innovation and technology in this space?

4. How are omics technologies, smart PoC devices, and exosome-mediated diagnoses emerging as novel molecular diagnostics modalities for NDDs? How do they improve accuracy?

5. What are the strategic implications of the emerging collaborations and M&As between academia and industry participants?

6. How do patents contribute to advancements in diagnostics and therapeutics for NDDs?

7. What are the growth opportunities for molecular diagnostics for NDDs?

Table of Contents

Strategic Imperatives

  • Why Is It Increasingly Difficult to Grow?
  • The Strategic Imperative 8™
  • The Impact of the Top 3 Strategic Imperatives on Molecular Diagnostics for the Neurodegenerative Diseases Industry
  • Growth Opportunities Fuel the Growth Pipeline Engine™
  • Research Methodology

Growth Opportunity Analysis

  • Dementia Disease Burden Forecast for 2050
  • Insights into NDD Research: Trends in Publications and Clinical Trials, 2019-2024
  • NDDs: Overview and Importance of Early Diagnosis
  • Segmentation
  • Challenges in Early NDD Diagnosis
  • Diagnostic Modalities in the NDD Landscape
  • Sources of NDD Molecular Biomarkers
  • Scope of Analysis
  • NDD Diagnosis: Biomarker Sources, Sample Extraction, and Analytes
  • Biomarker Sources: A Comparative Analysis
  • Integrated Landscape of NDD Biomarkers

Growth Generator

  • Growth Drivers
  • Growth Restraints

Technology Analysis: CSF Biomarkers

  • CSF-based Molecular Diagnostics to Detect NDDs
  • Key Companies Developing CSF-based Molecular Diagnostics for NDDs
  • Key Biomarkers for Neurodiagnostics: CSF-based Biomarkers, Global, 2024

Technology Analysis: Blood Biomarkers

  • Blood-based Biomarkers in NDD Diagnosis
  • Key Companies Developing Blood-based Molecular Diagnostics for NDDs
  • Emerging Companies Developing Blood-based Molecular Diagnostics for NDDs
  • Key Biomarkers for Neurodiagnostics: Blood-based Biomarkers, Global, 2024

Technology Analysis: Salivary Biomarkers

  • Salivary Biomarkers: An Accessible and Painless Diagnostic Approach for NDDs
  • Emerging Companies Developing Saliva-based Molecular Diagnostics for NDDs

Technology Analysis: Urinary Biomarkers

  • Urinary Biomarkers for Early Diagnosis of NDDs
  • Emerging Companies Developing Urine-based Molecular Diagnostics for NDDs

Technology Analysis: Ocular Biomarkers

  • Ocular Biomarkers: A New Frontier in NDD Diagnosis
  • Neurobiomarkers: Molecular Alterations in the Ocular Space
  • Emerging Companies Developing Ocular-based Molecular Diagnostics for NDDs

Technology Analysis: Skin-based Biomarkers

  • Skin-based Biomarkers for NDDs

Summary of Key Biomarkers for NDD Molecular Diagnostics

  • Key Insights: Biomarker Utilization by Industry Participants in the NDD Diagnostics Space
  • Molecular Biomarkers: From Bench to Clinic, Impact Analysis

Clinical Trial Analysis

  • Notable Clinical Trials in NDD Molecular Diagnostics
  • European Platform for Neurodegenerative Disorders (EPND): A Collaborative Approach to Data and Sample Sharing

Emerging Trends in NDD Molecular Diagnostics

  • Databases and Biobanks: Catalysts for Biomarker Discovery in NDD Diagnosis
  • Epigenetic Alterations as NDD Biomarkers
  • Big Data-powered Multiomics for NDD Diagnosis
  • Exosomes: A Potential Candidate for Early NDD Diagnosis
  • Portable Molecular Diagnostic Devices Enabling Smart Diagnostics for NDDs

Key Participants' Strategic Recommendations

  • Synaps Dx, US
  • AgenT Biotech, France
  • Urvogelbio, India
  • Resonant, US
  • Neurodex, US

Stakeholder Initiatives

  • Notable NDD Diagnostics Collaborations and Clinical Alliances
  • Recent NDD Diagnostics Mergers and Acquisitions
  • Global Companies in NDD Diagnostics: Insight into Regional Adoption

Funding Analysis

  • Snapshot of Public Funding for Molecular Diagnostics of NDDs in the US, 2019-2024
  • Special Focus on NIH Funding for Molecular Diagnostics of AD, 2019-2024
  • EU R&D Projects, 2019-2023
  • Snapshot of Private Funding for Molecular Diagnostics of NDDs, 2021-2024
  • Snapshot of Private Funding for Molecular Diagnostics of NDDs, 2020-2023

Patent Analysis

  • IP Trends in the Molecular Neurobiomarker Industry, 2019-2024
  • Patents by Key Participants in the NDD Diagnostics Space, 2019-2024
  • Analysis of IP Trends in the Molecular Neurobiomarker Industry, 2019-2024

Analyst Perspectives

  • Molecular Diagnostics in NDDs: Technology, Innovation, and Application Impact Analysis
  • Commercial Availability of Different Molecular Diagnostic Technologies in the NDD Landscape
  • Molecular Diagnosis of NDDs: A Technology Road Map

Growth Opportunities

  • Growth Opportunity 1: Smart Diagnostics at the Point of Care for NDD Detection and Management
  • Growth Opportunity 2: Integrated Diagnostics for Comprehensive NDD Assessment
  • Growth Opportunity 3: Exosomics and Metabolomics in the NDD Space

Appendix

  • Technology Readiness Levels (TRLs): Explanation

Next Steps

  • Benefits and Impacts of Growth Opportunities
  • Next Steps
  • Take the Next Step
  • Legal Disclaimer